Adjuvant denosumab in early breast-cancer

Giuseppina Campisi, Alberto Bedogni, Vittorio Fusco

Research output: Contribution to journalArticle

Abstract

We read with interest the D-CARE trial report by Robert Coleman and colleagues1 on the adjuvant administration of denosumab in patients with early-stage breast cancer. Despite the negative results, which pose concerns about high dose denosumab schedules in an adjuvant setting, this large and well- designed trial can provide useful clinical data that are usually difficult to obtain from observational studies, particularly regarding medication- related osteonecrosis of the jaw (MRONJ).
Original languageEnglish
Pages (from-to)e124-
Number of pages1
JournalLANCET ONCOLOGY
Volume21
Publication statusPublished - 2020

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Adjuvant denosumab in early breast-cancer'. Together they form a unique fingerprint.

  • Cite this

    Campisi, G., Bedogni, A., & Fusco, V. (2020). Adjuvant denosumab in early breast-cancer. LANCET ONCOLOGY, 21, e124-.